Yale Team reversed Type 2 diabetes and related fatty liver diseases in rodent models
Yale researchers were able to demonstrate in their study wherein type 2 diabetes and fatty liver disease were reversed in rats through a controlled-release oral therapy. Their findings were published by Science on February 26. This could give light to the diabetes research community as a basis for conceptualizing more effective treatment regimen for individuals suffering from type 2 diabetes; it may still take time to establish it in a clinical setting though.
At present time, treatments for Type 2 diabetes and related conditions, particularly, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are not that efficient at treating the root cause of those diseases. Earlier research by the Yale team researchers as led by Gerald I. Shulman, M.D., the George R. Cowgill Professor of Physiological Chemistry, and professor of medicine and cellular & molecular physiology at Yale School of Medicine went on to investigate if an agent originally used for promoting weight loss about seventy years ago could be reformulated and resulsts observed in rodent models of type 2 diabetes, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Earlier studies were able to establish that the toxicity associated with the agent, mitochondrial protonophore 2,4-dinitrophenol (DNP), was associated with its peak plasma concentrations. Dr. Shulman explained, "Besides reversing fatty liver disease in a rodent model of NALFD, a low-dose intragastric infusion of DNP that was 100-fold lower than toxic levels also significantly reduced blood glucose, triglyceride, and insulin concentrations in a rodent model of NAFLD and type 2 diabetes… Given these promising results in animal models of NAFLD/NASH and type 2 diabetes we are pursuing additional preclinical safety studies to take this mitochondrial protonophore approach to the clinic." Thus, the next phase of their study would involve a safer oral, controlled-release form of DNP (i.e. the CRMP) to be administered once daily. CRMP was found to deliver positive results in rat models of nonalcoholic fatty liver disease and nonalcoholic fatty liver disease without the adverse effects.
Note: This story is adapted from a news story published in ScienceDaily.
Source: Yale University. (2015, February 26). Type 2 diabetes, fatty liver disease reversed in rats. ScienceDaily. Retrieved February 28, 2015 from www.sciencedaily.com/releases/2015/02/150226144905.htm
rating: 0.00 from 0 votes | updated on: 1 Mar 2015 | views: 1407 |